Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Crinetics Pharmaceuticals Inc maintains a gross margin of 82.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2169.55%, while the net margin is -1993.43%. These profitability ratios, combined with a Return on Equity (ROE) of -40.17%, provide a clear picture of how effectively CRNX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CRNX competes directly with industry leaders such as AMRX and ERAS. With a market capitalization of $4.26B, it holds a significant position in the sector. When comparing efficiency, CRNX's gross margin of 82.54% stands against AMRX's 36.50% and ERAS's N/A. Such benchmarking helps identify whether Crinetics Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
